Friedreich’s ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.
Anyone considering participating in a clinical trial should discuss the matter with their physician. FARA does not endorse or recommend any particular studies.
Study Details:
The focus of this study is to assess cardiac dysfunction in individuals with FRDA using 4 modalities: hand crank exercise, cardiac magnetic resonance (CMR) imaging, echocardiography (ECHO), and serum measurements of cardiac status, including high sensitivity troponin, a measure of cardiac myocyte damage; N-terminal prohormone of brain natriuretic peptide (NTproBNP), a measure of heart failure; and creatine phosphokinase (CPK), a general measure of muscle damage. While there have been individual studies of some of these modalities, there are no studies that correlate these parameters and it is not known which parameters are more sensitive to cardiac dysfunction. This preliminary study will help define the parameters most useful in assessing the cardiac involvement in FRDA. In addition, the study will investigate noninvasive tests and procedures that may serve as biomarkers for the neurologic disease. In other neurological diseases, non-invasive examination of the number and structure of nerve cells in the cornea has been assessed as an indication of disease progression.
Friedreich’s Ataxia – Key Inclusion Criteria:
- Males and females, age 12 to 30
- Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)
- Definitive diagnosis of FRDA, based on clinical phenotype and genotype
- Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will not be required to perform the CPET)
Friedreich’s Ataxia – Key Exclusion Criteria:
- Signs and symptoms of cardiac failure
- Moderate to severe atrial or ventricular arrythmias
- History of angina pectoris
- Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
- Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
- Females who are pregnant
- Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
- Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
- Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
- Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual’s ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study
Normal controls – Key Inclusion Criteria:
- Males and females, age 12 to 30
- Willing and able to provide informed consent (Adolescents will need to provide assent and a parent to provide consent)
- Matched age, gender and ethnicity to the FRDA group
- Capable of undergoing the various modalities of cardiac assessment
- Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will be withdrawn from the study)
Normal controls – Key Exclusion Criteria:
- Individuals not deemed in good overall health by the investigator will not be accepted into the study
- Signs and symptoms of cardiac failure
- Moderate to severe atrial or ventricular arrhythmias
- History of angina pectoris
- Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
- Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
- Females who are pregnant or lactating
- Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
- Unable to sit with back support
- Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
- Unable to undergo exercise tests
- Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
- Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual’s ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study
Additional inclusion and exclusion criteria may apply and will be evaluated by a study doctor.
Length of Study Commitment:
- One year